Introduction {#Sec1}
============

Breast cancer (BC) is the most common cancer among women, with a lifetime risk of up to 12% and a risk of death of up to 5% \[[@CR1]\]. Its incidence has been increasing but after a period of continuous rise in many industrialized countries BC mortality has been stable or has even decreased in the last 10--15 years \[[@CR2], [@CR3]\]. The introduction of mass mammographic screening programmes also resulted in earlier detection and diagnosis of small and less aggressive tumours. This, in combination with therapeutic improvements, has led to a substantial increase in BC survivors over the last few decades (Fig. [1](#Fig1){ref-type="fig"}). A long-term survivor is commonly defined as a person who is still alive 5 years after cancer diagnosis \[[@CR4]\]. For BC, the relative survival at 5 and 10 years after diagnosis is 88% and 77%, respectively, both substantially higher than the 5-year relative survival of all cancers together (64%) \[[@CR4]\]. Thus, it seems logical to consider factors known to play an important role in predicting 5-year survival of BC patients and to question their importance in survival 10 years after diagnosis and even longer. Furthermore, in recent years major advances in the prognostic value of several molecular markers have been achieved, hence the need to incorporate this data into our current knowledge. Therefore, we have summarized available knowledge on the determinants of survival 10 years or more after breast cancer diagnosis. We supported our analyses and considerations with data from the population-based, long-standing Eindhoven cancer registry in the Netherlands.Fig. 1Proportion of breast cancer patients (3-year moving average) diagnosed between 1973 and 1993 who survived 10 years or longer in Southeastern Netherlands

Methods {#Sec2}
=======

We initially searched PubMed, using the search MESH term for 'breast neoplasms' AND 'prognoses' AND 'long-term'. Only papers published in English between 1995 and 2006 (September) which researched female adults (19+ years) were included. We retrieved 528 articles and studied the abstracts (sometimes also the methods section). We selected only articles that assess or show the results for those surviving 10 years or longer with cohorts having a mean/median follow-up of 10 years or longer. If mean/median follow-up time was not reported, we examined the proportion of patients who survived 10 years after diagnosis, and this ought to be larger than 50%. If, for a specific topic of interest, no relevant studies with a follow-up of at least 10 years were found (such as BRCA mutation or gene profiling, which have been studied only during the last decade), then studies with the longest available follow-up were chosen. Furthermore, the following inclusion criteria were used: overall and/or BC-specific survival was reported; relative risk or hazard rate and statistical probability values were given; at least 250 BC patients included at the beginning of study. We also searched the reference lists collected by this search strategy and selected those that were relevant to both our study question and inclusion criteria. Reviews and books that gave general overviews were also included in the reference list.

We present data from the Eindhoven Cancer Registry (ECR) to illustrate the role of factors such as age, tumour size, lymph node involvement and time since diagnosis. Within the Netherlands, ECR is unique because it has collected follow-up data since 1970, including clinical aspects of cancer patients. This is a population-based cancer registry covering a population of almost 2.4 million people in 2004 \[[@CR5]\]. Cumulative survival proportion was calculated using the Kaplan Meier method. Relative survival was calculated by comparing the survival of BC patients to the general population.

Throughout the text the term long-term and/or survival will frequently be mentioned; this corresponds to at least 10-year survival unless otherwise indicated.

Results and discussions {#Sec3}
=======================

Determinants of survival BC 10 years or longer {#Sec4}
----------------------------------------------

### Patient characteristics {#Sec5}

#### Age at diagnosis {#Sec6}

Very young women, i.e. younger than 30/35 years \[[@CR6], [@CR7]\], exhibited a particularly poor survival as do those older than 70 (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR8], [@CR9]\]. Young BC patients were more likely to have a more negative clinical presentation, such as affected lymph nodes, negative for oestrogen receptors, and have large tumour with a high fraction of p53 nuclei and overexpression of c-erb-2 oncoprotein \[[@CR6], [@CR10], [@CR11]\]. However, current adjuvant treatment seems to diminish the poor prognostic value of young age \[[@CR6]\]; young women who did not receive adjuvant treatment had a significantly increased risk of dying; those diagnosed at 35--39 years and \<35 years had a 1.4 and 2.2 higher risk of death, respectively, compared to those of 45--49 years \[[@CR6]\]. Older patients exhibited higher mortality rates \[[@CR12]\], probably because of less extensive treatment (either related to advanced age itself or the presence of serious concomitant diseases (comorbidity)) \[[@CR13]\].Fig. 2Relative survival of breast cancer patients (n: 13,279) diagnosed in 1990--2002 and followed until 2004, according to age at diagnosis in southeastern Netherlands

#### Comorbidity {#Sec7}

Concurrent health conditions (comorbidity) at the time of BC diagnosis have a significant impact on early \[[@CR13]\] as well as long-term survival of BC patients \[[@CR12]\]. The most prevalent conditions were cardiovascular disease (7%), previous cancer (7%) and diabetes mellitus (6%), all becoming more common with increasing age \[[@CR13]\]. Compared to those without comorbidity whose 5-year relative survival was 87%, those with diabetes mellitus or cardiovascular disease represented 78% and 83% of the respective survival estimates \[[@CR13]\]. Patients with severe comorbidity exhibited a 2.7--3.4 higher risk of death in 10 years compared to those without comorbidity \[[@CR12], [@CR14]\].

#### Period of diagnosis {#Sec8}

Access to care and treatment of BC has improved over time in most industrialized countries, which is reflected in the higher long-term survival of BC cases across all age groups and the tumour characteristics of those diagnosed more recently \[[@CR15]--[@CR18]\]. In Finland, relative survival 10 years after diagnosis among patients younger than 50 years increased from 49% for those diagnosed in 1953--1959 to 68% for the 1983--1989 cohort \[[@CR15]\]. Furthermore, 60% of node-positive BC patients diagnosed in 1978--1979 in Italy survived 10 years or longer compared to the 50% probability 10-year survival for those diagnosed in 1968--1969 \[[@CR17]\]. In addition, changes in BC diagnosis, e.g. screening\[[@CR19], [@CR20]\] and better staging \[[@CR17]\], may partly be responsible for the observed increase in the proportion of survivors.

#### Time after diagnosis {#Sec9}

The longer a woman survives BC the more the prognosis improves, illustrated by conditional survival \[[@CR16], [@CR21]\]. Probably the subgroup of patients who survived longer had less aggressive tumours due to a different genetic make-up or better life-style. In Australia, 79% of women with localized BC survived 10 years after diagnosis, yet among those still alive 5 years after diagnosis 84% had a 10-year survival \[[@CR16]\]. The respective values for regional vs. advanced BC were 53% and 68% \[[@CR16]\]. Unlike other cancers, relative conditional survival remained stable below 100% after 12 years of survival and decreased again after about 19 years (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR5]\]. This may be a consequence of late recurrences and metastases, second cancers or late side-effects of treatment \[[@CR23]\].Fig. 3Conditional 5-year relative survival (calculated using period analysis \[[@CR22]\] of breast cancer patients diagnosed in southern Netherlands in 1985--2002 and followed until 2004, according to age. (*Dashed line*): diagnosed at 25--49 years, (*solid line*): diagnosed at 50--74 years

#### Socioeconomic status (SES) and race {#Sec10}

A population-based study of BC patients diagnosed in 1968--1999 in France showed a diminishing role of SES on excess mortality among women with BC over these periods \[[@CR24]\]. Long-term follow-up studies reported that women with BC from low social classes had a 20--50% poorer survival compared to patients from higher social classes \[[@CR25], [@CR26]\], although others contradicted this \[[@CR27]\]. Low SES patients were more likely to be diagnosed at a later stage, had more aggressive tumour characteristics and might have received sub-optimal treatment. However, differences in these prognostic factors did not fully explain the variation in survival according to social class \[[@CR25]\]. This is also the case when breast cancer survival is studied according to race/ethnicity. Ten years after treatment 58% of African Americans were still alive compared to 66% of the white Americans. After adjusting for other prognostic factors, 41% excess mortality from all causes was still observed among African Americans compared to caucasians \[[@CR28]\]. This suggests other residual factors such as lifestyle (higher body weight was observed among African Americans), comorbidity \[[@CR14]\], genetics or variation in the delivery of treatment, which influence outcome beyond variation in tumour aggressiveness \[[@CR29]\].

### Tumour-related characteristics {#Sec11}

#### Tumour size {#Sec12}

Tumour size is one of the strongest prognostic indicators (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR7], [@CR30]\], even after 20 years of follow-up \[[@CR8], [@CR31]\]. A larger tumour has been related to more positive lymph nodes \[[@CR32]\], thus their interaction further influences the survival from BC. Nonetheless, the independence of survival by node status is shown by the lower 10-year overall survival rate found for node-negative patients with a tumour of 2--5 cm compared to those with a tumour smaller than 1 cm, 66% vs. 79%, respectively \[[@CR33]\].Fig. 4Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970--1994 and followed until 2004, according to tumor size (based on pathological diagnosis). ■ tumor size: \<2 cm (n: 3263) • tumor size: 2--5 cm (n: 3420) ▴ tumor size: \>5 cm (n: 474) **x** tumor size: involvement of skin (n: 1133) and unknown/not applicable tumor size: 1410

#### Histological type {#Sec13}

The prognostic value of histological type can be grouped into four: excellent, good, poor and very poor prognosis \[[@CR34]\]. BC with an excellent prognosis, such as invasive cribriform, tubular \[[@CR35]\], tubulo-lobular and mucinous \[[@CR36], [@CR37]\] showed \>80% survival at 10 years \[[@CR9]\]. Tubular mixed, mixed ductal with special type, atypical medullary \[[@CR38]\] and alveolar lobular carcinoma have a good prognosis with a 60--80% 10-year survival. Those with invasive papillary, classic lobular and medullary cancers have a worse prognosis. Finally, 10-year survival among those with ductal, solid lobular, mixed ductal and lobular carcinoma is below 50% \[[@CR34]\]. In most populations infiltrating ductal carcinoma covers about 70% of all diagnoses \[[@CR36], [@CR39]\]. Inflammatory BC has a particularly poor prognosis: about 30% survived 10 years \[[@CR40]\].

#### Histological grade {#Sec14}

The most widely used grading systems are Scarff-Bloom-Richardson classification, Fisher grading nuclear system and Nottingham Combined Histologic Grade (NCHG) \[[@CR41]\]. The validity of grading has been subjected to inter-observer reproducibility and subjectivity \[[@CR42]\]. However, higher grades have been quite consistently associated with lower long-term survival \[[@CR7], [@CR8], [@CR31], [@CR43]--[@CR45]\]. Depending on other prognostic factors, such as nodal status or tumour size \[[@CR46], [@CR47]\], cumulative survival among patients with the lowest score was 90--94% 10 years after diagnosis and 30--78% among those with the highest score \[[@CR37], [@CR48]\].

#### Regional lymph node involvement {#Sec15}

Lymph node involvement is a valuable indicator of long-term survival (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR8], [@CR32]\]. Node- positive patients have about a 4--8 times higher mortality than those without nodal involvement \[[@CR8], [@CR9], [@CR49]\]. The more nodes involved the worse the prognosis. Prognosis for patients with 10 or more involved axillary nodes showed 70% more deaths at 10 years than for those with 1--3 involved nodes \[[@CR32]\]. The survival of node-positive patients improved due to better staging procedures and application of systemic treatment \[[@CR7], [@CR31], [@CR50]\].Fig. 5Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970--1994 and followed until 2004, according to nodal status (based on pathological diagnosis). ■ node negative (n: 4452) • node status: 1--3 positive nodes (n: 3266) ▴ node status: 4--9 positive nodes (n: 255) **x** node status: 10+ positive nodes (n: 189), unknown/not applicable node status: 1538

#### Lymphovascular invasion (LVI) and molecular markers of tumours angiogenesis {#Sec16}

At the St. Gallen meeting in 2005, LVI was added to the prognostics for node-negative patients \[[@CR51]\]. Compared to patients having no LVI, a 60% higher BC mortality was observed for node-negative BC patients having positive LVI \[[@CR52], [@CR53]\], although others did not observe the independent role of LVI \[[@CR46], [@CR50]\]. In this line of research, studies have also focused on the value of microvessel density \[[@CR44]\], blood invasion (BVI) \[[@CR54]\] and markers of angiogenesis (VEGFR (vascular endothelial growth factor receptor), CD105, Tie-2) \[[@CR55], [@CR56]\] in predicting long-term survival of BC patients, although the results are still conflicting.

#### Grouped prognostic factors {#Sec17}

Some of the prognostic factors have been combined into a prognostic index, such as the TNM classification and also the more current Nottingham Prognostic Index (NPI), both highly predictive for estimating long-term survival \[[@CR41]\]. TNM staging consists of information on primary tumour size, involvement of the regional lymph node and the presence of distant metastasis. Only 53% of patients with regional or locally advanced BC had survived 10 years after diagnosis compared to 79% of those with localised BC \[[@CR16]\]. Patients with metastasis (stage: M1) at diagnosis exhibited very poor 10-year survival (3.4%) \[[@CR57]\].Fig. 6Cumulative survival of breast cancer patients diagnosed in southern Netherlands in 1970--1994 and followed-up until 2004, according to second cancer. Follow-up for patients with second cancer begins at the date of second cancer diagnosis. ■ no second cancer (n: 8137) • second breast cancer (n: 744) ▴ second non-breast cancer (n: 819)

Tumour size, grade and lymph node status make up the NPI \[[@CR11], [@CR46], [@CR49]\]. In a large series of 2879 BC patients, 10-year survival proportion was 85% for those with the lowest NPI score and 19% for those with the highest score \[[@CR11]\].

### Recurrence, metastasis and second cancer {#Sec18}

Patients with recurrent, metastasized or second cancer generally exhibited lower long-term survival than those without \[[@CR9], [@CR21], [@CR58]--[@CR61]\]. Ten years after surgery, the probability for survival for another 10 years, thus 20 years after diagnosis, for node-negative patients aged ≥45 years, tumour ≤1 cm, grade 1 and without a recurrence or metastasis was 0.89. If a recurrence occurred, the probability of being alive at 20 years dropped to 0.72. If a metastasis was observed the probability of survival was only 0.18 \[[@CR21]\]. The prognosis decreases with larger primary tumour size, nodal involvement \[[@CR62]\], higher grade,\[[@CR21]\] early recurrence (within 5 years of surgery)\[[@CR63]\], location of recurrence (regional rather than local ipsilateral) \[[@CR59]\] and inadequate primary cancer treatment \[[@CR9], [@CR64]\]. In the dataset of the ECR, overall survival was better for women without second primary tumours than for women who developed a new primary cancer (Fig. [6](#Fig6){ref-type="fig"}). Only 68% of early BC patients with second malignancies had survived 10 years of follow-up compared to 78% of those without multiple cancers \[[@CR65]\]. Younger BC patients are reported to have poorer survival and a higher risk of second cancer \[[@CR59]\]. Corrected for race and grade, women in the 20-29 year old category who had a second BC had a probability of 10-year survival probability of only 23% compared to 57% for those without multiple cancers.

### Other tumour markers {#Sec19}

#### Hormone receptors {#Sec20}

The presence of hormone receptors such as oestrogen (ER) and progesterone (PR) receptors predicts the long-term outcome of hormonal therapy \[[@CR66]\], thus they have been more commonly used as a predictive marker rather than as a prognostic marker. Thus given a particular treatment, e.g. tamoxifen, ER-positive patients have a considerably better prognosis than ER-negative patients. The prognostic value is weak \[[@CR30], [@CR43]\] or negligible \[[@CR37]\], particularly in the early years after diagnosis \[[@CR67]\].

#### HER-2 expression {#Sec21}

Node-positive patients with BC cells showing amplification of the gene for human epidermal growth factor receptor type 2 (HER2), and/or overexpression of its product had a lower 10-year overall survival proportion, 50% versus 65% for those without HER2 amplification \[[@CR17], [@CR68]\]. After 10 years the difference in survival persisted, although it became somewhat smaller\[[@CR17]\]. Tumours that overexpress HER2 are more likely to contain p53 abnormalities, to be hormone receptor- and bcl-2-negative and to have lymphoid infiltration and a high mitotic index, all known to be markers of poor prognosis for BC \[[@CR17], [@CR69], [@CR70]\]. As for patients with node- negative tumours, HER2 did not seem to affect long-term survival significantly \[[@CR17], [@CR37], [@CR69]\]. HER-2 expression has been valuable in predicting treatment responses to trastuzumab, certain endocrine therapies and chemotherapy, adding to it's role as a predictive marker \[[@CR68]\].

#### Mitotic Activity Index (MAI) {#Sec22}

MAI is an indicator of tumour proliferative activity that represents the mitotic activity in a given area of the tumour. Combined with another prognostic factor (NCHG), MAI has proven to be an accurate tool for assessment of long-term survival \[[@CR48]\]. In a population-based study women with node-negative tumours \<5 cm and a MAI ≥10 exhibited 80% survival at 10 years compared to 90% for an MAI \<10 \[[@CR71]\].

#### Gene expression profile {#Sec23}

A very promising new finding is the microarrays method, in which a set of intrinsic genes is clustered and segregated into major subgroups; BC with a good and poor prognosis profile is correlated to the probability of distant metastases \[[@CR72]\] or a tumour with basal or luminal characteristics which are strongly associated with ER status \[[@CR73]\]. In a study of 295 patients diagnosed with stage I or II breast cancer, those classified as having a good prognosis profile had a 95% overall 10-year survival rate compared to 55% for those with a poor profile \[[@CR74]\]. This classification predicted outcome regardless of the nodal status, implying that more accurate criteria have become available for administering adjuvant systemic treatment.

#### Various molecular markers {#Sec24}

BRCA1 & 2 mutations were first identified in 1994 and are BC risk factors for some specific groups \[[@CR75]\]. Their role as prognostic indicator for long-term (more than 10-year) survival has not yet been established. A study of 496 women (median follow-up: 116 months), 56 of whom (11%) carried a BRCA1/BRCA2 mutation, showed worse BC-specific survival for women with BRCA1 mutations than for those without (62% at 10 years versus 86%; *P* \< 0.0001), but not for women with the BRCA2 mutation \[[@CR76]\]. However, another study which compared patients from BRCA1, BRCA2 and non-BRCA1/2 families as well as sporadic cases did not confirm the prognostic role of BRCA1/2 \[[@CR77]\].

Long-term follow-up studies have not demonstrated an independent effect of p53 mutations on long-term survival. The P53 mutation was related to a poor clinical profile for patients, hence in multivariate analysis its role on survival diminished \[[@CR10], [@CR69], [@CR78], [@CR79]\].

A high level of tissue urokinase-type plasminogen activator (uPA) and its inhibitors has been correlated with poor outcome for node-negative and node-positive patients. Those having the highest level of uPA have a five times greater risk of dying from BC compared to those with the lowest level \[[@CR69]\]. Other factors such as Ki67 (MIB-1), cathepsin-D, DNA ploidy and S-phase have been suggested as prognosticators of survival, with conflicting results, particularly among long-term survivors. Their use in general clinical settings is therefore not recommended \[[@CR80], [@CR81]\].

### Miscellaneous {#Sec25}

#### Lifestyle {#Sec26}

Generally, increased death rates due to BC (13--20%), other causes (49--86%) and all causes (14--70%) have been observed among obese patients \[[@CR82]--[@CR85]\]. Normal body weight tended be more beneficial in death from other causes than from BC: \[[@CR83], [@CR84]\] 9.5% of obese patients died from non-BC causes compared to 6.4% and 5.8%, respectively, of the normal or intermediate groups \[[@CR82]\]. Obesity was also related to a 2-fold increased risk of postmenopausal contralateral BC and a 60% higher occurrence of second other cancers \[[@CR84]\]. Therefore, normal weight may reduce the risk of second post-menopausal BC, second other cancers and overall mortality \[[@CR83], [@CR84], [@CR86]\].

Compared with women who engaged in less than 9 metabolic equivalent task (MET)-hours per week of activity, women who engaged in 9 or more MET-hours per week had a 40% lower risk of death from all causes, translating into a 6% absolute (unadjusted) reduction in mortality \[[@CR87]\], which emphasizes the need to advise physical activity.

So far, although studies have not convincingly shown the positive influence of eating fruit, vegetables and soy bean on long-term BC survival \[[@CR85], [@CR88]\], diets high in fruits, vegetables, legumes, poultry, and fish and a low intake of red meat, desserts and high fat dairy products are likely to protect against mortality from non-BC causes \[[@CR89]\].

Modification of BC's prognostic factors {#Sec27}
---------------------------------------

Various studies have questioned the role of BC risk factors in determining the biological tumour features as mentioned above. Indeed, BC risk factors seem to differ according to histological type, grade, size, nodal status and ER/PR receptor status \[[@CR90]--[@CR93]\]. For example, excessive alcohol intake and obesity increased the risk for the development of ER-positive tumours \[[@CR92], [@CR93]\]. As for late age at first full-term birth and obesity are related to an increased risk of large tumours \[[@CR91]\]. Hence, risk factors for BC may also affect breast biology and clinical behaviour, thus also BC prognosis.

Changing importance of prognostic factors over time after diagnosis {#Sec28}
-------------------------------------------------------------------

Commonly, the value of prognostic factors decreases depending on the length of the follow-up period \[[@CR31], [@CR94]\]. Survival curves according to prognostic factors usually show a large drop in survival for all stages during the first 5 years; afterwards the curve stabilizes. Studies agreed on the long-lasting influence of tumour size at diagnosis on survival, albeit attenuating over time \[[@CR31], [@CR94], [@CR95]\]. Grade, nodal status and metastases were also valuable in predicting survival up to 20 years after diagnosis \[[@CR31], [@CR95]\]. Although, others have reported that 10 years after diagnosis only tumour size \[[@CR94]\] or nodal status \[[@CR8]\] or old age \[[@CR8]\] remained as an independent predictor of long-term survival. Similarly, ER/PR status and MAI only had a significant prognostic role in the first 5--10 years after diagnosis \[[@CR67], [@CR71], [@CR96]\]. Because even 10 years after BC diagnosis the probability of survival for BC patients does not seem to reach that of the general population, the role of other prognostic factors in determining survival for long-term survivors still needs to be determined.

The role of early detection {#Sec29}
---------------------------

Increased awareness among women and improvement in diagnostic procedures have enabled earlier and better detection of BC. Trials on population screening have reported 21--29% reduction in BC mortality for women invited for screening within 14--16 years of follow-up \[[@CR19], [@CR97]\]. Screening identified tumours at an early stage consequently, survival improved \[[@CR98], [@CR99]\]. Screening also identified patients with slowly growing tumours who might receive unnecessarily aggressive cancer treatment. Thus, Joensuu et al. \[[@CR100]\] examined recurrence rates among patients detected by screening compared to those detected outside screening. After adjusting for tumour aggressiveness (tumour size, nodal status, grade, age, treatment, PR status, HER-2), hence eliminating bias towards detection of indolent cancers (length bias), the benefit of screening for the prognosis for BC patients remained evident.\[[@CR100]\] This suggests that other factors explain the indolent behaviour of BC detected by screening. Hence, until this factor is established, detection mode should probably be considered as a prognostic factor and thus be taken into account in patient management.

The role of treatment {#Sec30}
---------------------

Improvement in BC treatment has undoubtedly also increased the long-term survival of BC patients \[[@CR101]\], as reflected by the improved overall survival across all BC stages \[[@CR16]\]. Using historical data from population-based studies in periods when effective treatment was not available, it was estimated that without treatment only 4% of BC patients would survive 10 years or longer \[[@CR102]\]. BC treatment guidelines have been modified continuously in the last 28 years, tailored to most of the prognosticators mentioned earlier \[[@CR51]\]. Effectiveness of various treatment modalities has been summarized by others who conclude that radiation, chemotherapy and hormonal therapy may reduce long-term mortality by up to 57% \[[@CR66], [@CR103]--[@CR105]\]. Emerging new therapeutic approaches using a monoclonal antibody directed against HER-2 have yielded improved short-term survival for advanced stage \[[@CR106]\] as well as operable BC patients \[[@CR107]\]. Quality of treatment as indicated by loco-regional failure \[[@CR108]\], surgeon workload \[[@CR109]\] or hospital volume \[[@CR110]\], may affect survival although its role on long-term survival still needs confirmation. In conclusion, on the one hand we have observed a shift in stage towards less aggressive cancers; on the other hand, better and more (systemic) treatment has become available, leading to improved survival for BC patients.

Conclusion {#Sec31}
==========

The prognosis of BC has become relatively good, with current 10-year relative survival about 70% in most western populations \[[@CR16], [@CR111]\], especially if up-to-date statistical method such as the period analyses is used \[[@CR111]\] (Table [1](#Tab1){ref-type="table"}). Even better, the longer patients survive their BC the higher their survival chance \[[@CR16]\]. Our review shows conventional prognostic factors of survival, such as tumour size, lymph node status and grade, remain the most important determinants of 10-year survival for BC patients (Table [2](#Tab2){ref-type="table"}). Most studies agreed on the value of MAI and LVI for prediction of long-term survival. The influence of host factors including age, race/ethnicity or socio-economic factors and tumour-related factors such as histological type and angiogenesis diminishes after correction for other factors. For most recent markers such as Her2, gene profiling, p53 mutation and uPA level longer follow-up is needed. Recurrence, metastases and a second cancer double the burden of disease thus increase risk of mortality. Similarly, co-occurrence with other diseases is in no doubt decrease survival.Table 1Overview of studies reporting long-term prognostic factors for breast cancer (BC) patientsNo.Author, yearNo. of patientsMean/median follow-up (yrs)Univariate (UV) analysis significantMultivariate (UV) analysis significantNot significantRemarks1Haerslev and Jacobsen 1995 \[[@CR70]\]^a^49010.6MS, T, N, Htyp,\
MI, G, PR, Her2All patients: N & PR\
In N+: MI & PR\
In N-: MS & GHer2Overall survival was measured. P53 was related to absence of tubular formation, high G, ER-negative, high PCNA (proliferating cell nuclear antigen) score2Pietilainen 1995 \[[@CR10]\]39211.1P53, N, T, Htyp, tubular formation, intraductal growth, margin formation, necrosis, DNA ploidy, S-phase fractionAll patients: N, T, MI\
In N+: T, MI\
In N−: T, p53, GOverall survival was measured. P53 is related to younger age, MI, AI, G, nuclear pleomorphism3Haerslev 1995 \[[@CR79]\]^a^49011PCNAT, G, PRHer2 & PCNA (Proliferating cell nuclear antigen)Overall survival was measured. PR was only an independent factor in N-positive pts. Her2 & PCNA were related to more positive N, higher G, ER-/PR-negative4Gamel 1996 \[[@CR39]\]163,808NR. Range 1mos-19 yrsHistological type by stage (localized & regional BC)Breast cancer specific survival was measured5West 1996 \[[@CR12]\]1196NR. Diagnosed: 1973--1986. End FU: 1994.ComorbidityLevel of comorbidityAdjusted for age, race, stage, N, therapy. Values for these factors were not shownOverall survival was measured. Charlson comorbidity index was used. There is no difference in the significance of comorbidity on survival of Caucasians and African American (AA)6Haerslev 1996 \[[@CR112]\]^a^487\>10Ki-67, PCNAT, G, PRKi-67 & PCNA.Overall survival was measured. PR only an independent factor for N+ patients. Ki-67 was related to T, MI, G7Northridge 1997 \[[@CR36]\]Mucinous BC: 4082. Infiltrating duct BC: 139,154NR. Diagnosed: 1973--1990HTyp, period of diagnosis, Stage, GAgeBreast cancer specific survival was measured8Kollias 1997 \[[@CR11]\]^a^2879 age ≤70, T \<5cm\>10Age \<35, NPIT, G, NAgeOverall survival was measured. Younger than 35 yrs had higher grade, more LVI and worse NPI group. After 10yrs NPI did not change OS9Zahl and Tretli 1997 \[[@CR95]\]8802 age \<70Diagnosed: 1965--74. End FU: 1991Survival categorized by age, stage and follow-up timeExcess hazard from breast cancer was measured. After 8 yrs being younger than 35 does not influence survival. Stage was an important prognosticator up to 20 yrs10Pinder 1998 \[[@CR47]\]46512N by grade, Treatment by gradeOverall survival was measured. The study aimed to confirm value of Nottingham grading system for survival. N+G3 patients benefited from prolonged chemotherapy11Gaffney 1998 \[[@CR113]\]BRCA1: 30\
BRCA2: 20\
Control: 18278\
BC ptsBRCA1: 9.8\
BRCA2: 7.5\
Control: NRBRCA1 vs. BRCA2 vs. controlOverall survival was measured\
Case and control were matched for date of birth, date of diagnosis and tumour size. Patients with BRCA+ were younger. Patients with BRCA1 had higher grade12Wojcik 1998 \[[@CR28]\]6577 patients\
Whites: 5879\
African American (AA): 698At 10 yrs 59--67% patients were aliveRace, G, N, T, stage, waiting time, smoking, being a widow, having other family as dependentRace, age, stageUV: alcohol, family historyOverall survival was measured. AA is more likely to be younger at diagnosis, have larger tumour, higher stage and more lymph nodes13Mansi 1999 \[[@CR114]\]35012.5Bone marrow micrometastasesN, TBone marrow micrometastases, LVIOverall and breast cancer-specific survival was measured. Bone marrow metastases may be useful as prognostic factor for BC pts without information on T and N14Kollias 1999 \[[@CR46]\]^a^319 T ≤1cm\>10G, N, LVI, NPIG, NLVIOverall survival was measured15Tabar 1999 \[[@CR45]\]2468NR. Diagnosed: 1977--85. End FU: 1996T, N, G, detection mode, HTypTXN, age\*N, Htyp\*N, T\*N\*GOverall survival was measured. Screening arrests disease progression. Tumour progression is more rapid in BC patients \<50 yrs. OS of T1a(1--5 mm) vs. T1b(6--10 mm) NS.16Holmes 1999 \[[@CR85]\]198213.1BMI ≥303rd to 5th quintile of protein protein intake after diagnosis, N, T, GBMI, protein intake prior diagnosis, alcohol intakeAll cause mortality was measured. MV for BMI was corrected for age, diet interval, oral contraceptive use, hormone replacement therapy, MS, age at menarche, aget at birth and parity, smoking, T, G, N, ER, PR\
BMI \<21 and 1st quintile of protein intake were reference. Significant trend of higher mortality from lowest to highest quintiles of fibre, lutein and zeaxanthin, calcium and protein intake, with 13--35% lowest mortality in the lowest quintile17Nomura 1999 \[[@CR58]\]1857 \<80 yrs stage I-III12Second cancer and recurrenceAge, ER, N, recurrence, second cancerOverall survival was measured\
Recurrence is related to higher stage, younger age at diagnosis, Htyp, and therapy. Second cancer is related to younger age. Death related to recurrence and second cancer is increased 12 yrs after diagnosis.18Reed 1999 \[[@CR37]\]613 T1-2N015.5Age \>50, T, GG, T, treatmentUV: treatment, ER, PR, Her2, P53Overall survival was measured. Her2 was related to PR-, ER-negative, P53, G. P53 was related to PR-. Treatment was ovarian & locoregional irradiation that had lower mortality rate19Aebi 2000 \[[@CR7]\]3700 pre- & perimenopausal12Age \<35 vs. ≥35N, T, G, age \<35\*ER+Age, EROverall survival was measured. Younger patients with ER+ who were not amenorrhoea had a significantly shorter survival20Ferrero 2000 \[[@CR78]\]297 N-11T, ER, P53T, ERAge, PR, GBreast cancer-specific survival was measured. P53 was related to grade, T, ER-negative. P53 was continuous variable21Kroman 2000 \[[@CR6]\]10,356 age \<50NR. Diagnosed: 1978--96.Age, T, N, GPeriod of treatment and surgeryRelative survival was measured for excess mortality due to BC. When chemotherapy was given BC at young age does have worse prognosis22Ferrero-Pous 2000 \[[@CR69]\]48810ER, uPA, G, N, PR, P53 by Her2All patients: uPA, N, T, Her2, age\
In N−: uPA, T\
In N+: N: uPA, T, age, Her2Overall survival was measured. For patients who received chemotherapy uPA, T & N determined OS. For patients who received hormonal therapy uPA, Her2 & N determined OS23Kato 2001 \[[@CR44]\]^a^37710T, N, GAMC, T, N, GNecrosisOverall survival was measured. AMC is a good prognostic factor for N- and T2-3 patients24Liu 2001 \[[@CR96]\]79116.3T, N, G, ER, Her2, p53, MIB-1, MAI, AIAll patients: N, T, G, ER, Her-2\
In N−: G\
In N+: N, age, ER, Her2UV: age. MV All patients: AI, MI, MIB-1, ER, G MV in N- & N+: AI, MI, ER, G.Breast cancer-specific mortality was measured. When patient FU was truncated at 5 yrs, MI was prognostic factor for N+ and N-25Page 2001 \[[@CR115]\]311 no adjuvant therapy.11.6High risk group (ER- or T≥3cm) vs. low risk (ER+ and T \<2 cm)T, risk group (high vs. low)G, MIOverall survival was measured. MI was only significant when FU was truncated at 5 yrs. Grade was significant prognostic factor for short- and long-term survival26Frkovic-Grazio and Bracko 2001 \[[@CR48]\]270 T1N0M012.5G, Tubular score, MITubular score and MIBreast cancer-specific survival was measured. This study confirmed the use of Nottingham grading system in their cohort27D'Eredita 2001 \[[@CR49]\]402≥16T, N, Htyp, G, LVI, NPIT, N, GUV: Age, MS, ER, type of surgery\
MV: LVI & HtypOverall survival was measured. NPI gives similar survival prognosis as T, N, G28Thomson 2001 \[[@CR26]\]23786At 10 yrs about 50% patients were aliveAge stratified by SESIntermediate vs. high SES group corrected for age, ER, N, T, stageDeprived vs. high SES group corrected for age, ER, N, T, stageDeprived women have more ER- tumours. ER distribution and treatment method accounted for 20% of disparities in survival29Vorgias 2001 \[[@CR30]\]269 stage II12NRT, N, age, ER/PRMS, therapyOverall survival was measured30Vincent-Salomon 2001 \[[@CR43]\]685 T≤3 cm10.8G, N, ER, necrosisN, necrosis, GUV: Vascular density, LVI, age, PROverall survival was measured. Intratumoral vascular density was related to larger tumour size and higher grade31Eerola 2001 \[[@CR77]\]Familial BC: 359\
Sporadic BC: 59517NR\
Diagnosed: 1953--1995 End FU: 1997Stage, age, period of BC diagnosis, FU time (after 2 and 3 yrs of diagnosis)BRCA1, BRCA25-year relative survival was measured for excess mortality due to BC32Kitchen 2001 \[[@CR35]\]952012Tubular BC type vs. other type, by nodal status and chemotherapyOverall survival was measured. Tubular BC type had better prognosis than other type. This type was more likely to have low G & ER+33Kato 2002 \[[@CR50]\]^a^42210P53, MI, necrosis, T, N, LVIMI, T, NUV: AIOverall survival was measured\
In MV P53 & MI were independent prognostic factors for N-patients only. P53 was related to MI, AI, necrosis, G, T, N, ER/PR34Kato 2002 \[[@CR54]\]^a^39810BVI, T, N, G, chemotherapyBVI, T, N, G, chemotherapyUV: necrosisOverall survival was measured35Costa 2002 \[[@CR67]\]67011.4N, T, age, ER/PRN, T, ageMS, ER/PRBreast cancer-specific survival was measured. After 5 yrs of FU ER and PR were not independent prognostic factors36Menard 2002 \[[@CR17]\]1928Diagnosed in 1968--69 and 1978--79Her2, N, T, MS, lymphoid infiltration, PR-G, T, N, lymphoid infiltrationOverall survival was measured. HER-2 was related to large tumours, higher G, lymphoid infiltration, higher mitotic index, PR-37Van de Vijver 2002 \[[@CR74]\]295 age \<53, stage I-II6.7Gene profile (Good vs. bad prognosis) for all patients, N+, N−Gene profile, T, N, chemotherapyVI, G, age, hormonal therapyOverall survival was measured38Van't Veer 2002 \[[@CR72]\]117 age \<55NRBetter classification of patients with high risk of metastasis and in need of chemotherapy39Hatteville 2002 \[[@CR21]\]318015.8OS \<5 year: N, G, recurrence or metastasis OS≥5 yr: G and recurrence or metastasisAge, TIf patient remains without recurrence or metastasis, effect of prognostic factors decreases over time. With metastases, this effect increases40Sotiriou 2003 \[[@CR73]\]996.1Gene profile (luminal 1--3 vs. basal 1--2 & Her2 type)Luminal-like 1--3 was predominantly ER+. Basal-like 1--2 and Her2 was predominantly ER-41Dignam 2003 \[[@CR83]\]3385 N−, ER+13.8BMI \<18.5 and BMI ≥30 higher total mortality and other deaths.BMI on deaths after BC events.Total mortality, death after BC events and other deaths as well as recurrence rate and occurrence of a second cancer was were measured. MV was adjusted for treatment, age, MS, race, T, ER and PR. Reference group was BMI 18.5--24.9.42Olivotto 2003 \[[@CR57]\]620 stage IIIB-M1\>20Supraclavicular BC, Stage IIIB and M1Overall and breast cancer specific survival were measured. Patients with supraclavicular metastases had significantly better survival than patients with M1. Survival of these patients resembles that of BC stage IIB. (FU for living patients 20 yrs, for all patients 4.5 yrs)43Weiss 2003 \[[@CR32]\]905 N+ Chemotherapy+22.6N+ (N1--3 vs. N4--9 vs. N \>10), also by treatment and follow-up timeN, T, MSMV: NXT, MSXT, additional vincristine and prednisonOverall survival was measured. N was related to T. MS was related to receptor status44Taylor 2003 \[[@CR16]\]54,228At 10 yrs 65% patients were alivePeriod of diagnosis, stage by age, FU time by stageRelative survival was measured for excess mortality due to BC\
The longer the survival the better the prognosis. Improvement in relative survival for all patients and all stages since 197245Dales 2004 \[[@CR56]\]905 aged 25--8111.7In N- : CD105+ vessels. In all pts: CD31, Tie-2/TekIn all pts: G, CD105 vessels, ER\
In N−: G, CD105 vessels, PRIn all pts: T, Htyp, CD31, PR, age. In N−: T, CD31 vessels, ER, ageOverall survival was measured. MV: Tie-2/Tek showed significant role for predicting OS in all patients and N- patients46Brenner and Hakulinen 2004 \[[@CR15]\]18,578 age \<50NR. Diagnosed: 1953--1999.Period of diagnosis, stage, stage\*period, time after diagnosisImprovement of prognosis for BC patients younger than 50 over the past decades. Relative survival remains lowered even 40 yrs after diagnosis47Robson 2004 \[[@CR76]\]584 Ashkenazi Jewish116BRCA1, T, N, ER, age, chemotherapyBRCA1, T, N, AgeTamoksifen, BRCA2Breast cancer-specific survival was measured. No effect of BRCA on non-BC death. BRCA1 only predicted BC death in patients without chemotherapy48Chia 2004 \[[@CR33]\]1187 LVI-, N-, Adjuvant systemic therapy-10.4T, GTXGOverall and breast cancer specific survival were measured. Patients with higher grade and size have greater chance to die from other & those with low risk disease greater chance of death from BC49Yoshimoto 2004 \[[@CR18]\]15,416NR. Diagnosed 1946--2001.Period of diagnosisOver the decades, there were less extensive surgery and lymph node examination, less radiotherapy, more chemo- and hormonal therapy50Houterman 2004 \[[@CR116]\]527 age ≥404.7Comorbidity, N, Therapy, age≥70, comorbidity\*NIn age \<70: comorbidity, N In age ≥70: comorbidity, ageIn age \<70: therapy\
In pts age≥70: N, therapyRelative survival was measured for excess mortality due to BC\
Older patients with comorbidity were not treated differently but had a worse prognosis51Schoppmann 2004 \[[@CR53]\]37422.4LVI, G, N, TherapyLVI, G, NLMVD (Lymphatic Microvessel Density), T, Htyp, ER, age, MSOverall survival was measured. LVI is related to young premenopausal BC, lower G, N+52Warwick 2004 \[[@CR31]\]2299\>10G, N, T, MetastasesG, N, T, MetastasesBreast cancer specific survival was measured. All studied factors predicted long-term survival, but their value decreased over time53Berclaz 2004 \[[@CR82]\]679214BMI 25--29, BMI ≥30 lower overall survivalBMI ≥30BMI 25--29Overall survival and also disease free survival were measured. Reference group was BMI ≤ 24.9. MV adjusted for ER, T, N, MS, treatment, chemotherapy, hormonal- in combination with chemotherapy54Dignam 2005 \[[@CR84]\]4077 N-, ER-NRBMI ≥35 and AA had higher overall mortality and non- BC deathBMI and race on death after BC eventsTotal mortality, death after BC events and other deaths as well as recurrence rate and occurrence of a second cancer were measured. MV was adjusted for treatment, age, MS, race, T, ER and PR\
Reference group was BMI ≤24.955Holmes 2005 \[[@CR87]\]298796 monthsPhysical activity after diagnosis (MET ≥9) on BC and total mortalityBreast cancer and total mortality were measured. MV corrected for age, interval between diagnosis and physical activity assessment, smoking, BMI, MS, hormone therapy use, age at first birth, parity, energy intake, stage and treatment. MET: metabolic equivalent task hours per week. Patients with BMI ≥25 and more physical activity before diagnosis there was a significant trend for less breast cancer death56Robsahm and Tretli 2005 \[[@CR27]\]5042NR. Diagnosed: 1964--92. End FU: 1992NRLocation of home, age at first child, physical activity at workMV corrected for: age, period of diagnosis, birth cohort, educational levelBreast cancer-specific survival was measured. Incidence of BC increases with higher educational level, and case fatality decreases by increasing education level57Vu-Nishino 2005 \[[@CR38]\]1490 received breast- conserving treatment13.9Medullary BC vs. other BC typeOverall survival was measured. Medullary BC type had better prognosis than other type. This type was more likely to have ER+, PR+ & less BRCA1/2 mutation. Medullary type was only a prognostic factor for the first 5 yrs58Galper 2005 \[[@CR63]\]2102 stage I-II, 314 with local recurrence (LR)13.1NRNo LR treatment, Invasive LR, time (yrs) to local recurrence, age at initial BC diagnosisT, detection method, number of nodes sampled, ER/PR, histological type, G, LVI, marginsMeasure of survival: distant failure, second malignancy, or death\
Patients with a longer time to recurrence have prolonged survival59Voogd 2005 \[[@CR62]\]266 BC with LR11.2 after LR for living ptsNRLocation of LR, size of LR, skin involvement of LR, N+ for primary tumourOverall survival was measured. Early detection of local recurrence may improve the treatment outcome60Louwman 2005 \[[@CR13]\]8966Diagnosed 1995--2001. End FU: 20042 or more comorbidities, diabetes mellitus and previous cancerPrevious cancer, CVD, DM, cerebrovascular disease, dementia, 2 or more comorbidities, stage, treatment (RT, ST, age)Overall as well as relative survival was measured for excess mortality due to BC\
Primary treatment of BC patients with serious comorbidity was less extensive than treatment of those without comorbidity61Tammemagi 2005 \[[@CR14]\]90610Number of severe comorbidities, race, type of comorbidityAll patients: 3 or more comorbidities adjusted for stage, age, ER, surgery, chemotherapy, radiotherapyOverall survival was measured. AA had more diabetes and hypertension. After adjustment for these 2 comorbidities disparity disappeared62Meunier-Carpentier 2005 \[[@CR55]\]909/918 age: 25--8111.3Tie2--UV: VEGFR-2, VEGFR-2Overall survival was measured. VEGFR-1 and Tie2 were reported as independent prognostic factors corrected for T, G, Htyp, in all patients and N-63Tai 2005 \[[@CR40]\]6184 Inflammatory BCNR. Diagnosed 1973--1995. End FU: 2000Period of diagnosisBreast cancer-specific survival was measured. Prognosis has improved over the decades due to more aggressive therapy64Louwman 2005 \[[@CR71]\]492 T1--2 N0\>10 yrsMAIOS: age, T\
BCS: MAIOS: HTyp, therapy, period of diagnosis. BCS: therapy, period of diagnosis, age, T, HtypOverall (OS) as well as relative survival (BCS) was measured for excess mortality due to BC\
Higher MAI was a significant prognostic factor for N− and N+, but only during the first 10 yrs of FU65Arrigada 2006 \[[@CR8]\]2410 T ≤7 cm N1--219T, skin fixation, muscle fixation, G, N, ageTotal FU: T, N, G, age \<35, age≥55\
FU 0--5 yrs: T, N, G, age ≥55\
FU 5--10 yrs: N, G, age \<35, age ≥ 55\
FU 10--15 yrs: N \>10, age \>55. FU 15--20yrs: age≥65Overall survival was measured. Long-term effect of prognostic factors vanishing66Newman 2006 \[[@CR29]\]90,124. White American: 76,111. AA: 14,013Age, stage, SESMeta-analysis. African American is an independent predictor of poor outcome for overall survival and breast cancer specific mortality67Menvielle 2006 \[[@CR24]\]407,435 women followed for BC death (N:1408)Women who died of BC in 1968--96Level of education by period of diagnosisBreast cancer death among women with the highest education compared to women with the lowest education in 1968--74 was 0.43; and in 1990--96: 1.17 (NS)68Bouchardy 2006 \[[@CR25]\]3920 age \<70NR. Diagnosed in 1980--2000SESSES corrected for age, period of diagnosis, marital status, country of birth, Htyp, ER, detection method, stage, sector of care, therapyOverall survival was measured. Lowest SES had less frequently screen-detected cancers, less stage I, less lobular BC, less BCT, less lymph node dissection69Siegelmann-Danieli 2006 \[[@CR117]\]992, age ≥706.9Being in wheelchair, renal insufficiency, dementia, CHF, cardiac arrhythmia, DM, IHD, osteoporosis, PVD, cerebrovascular disease, COPD, Parkinson's disease, valvular heart diseaseIn stage 1A-2A: age, CHF, DM, PVD, stage, cardiac arrhythmia, Parkinson's disease, renal insufficiency\
In stage 2B-4: G, stage, N, wheelchair-bound, renal insufficiency, COPD, age, DMSystemic therapyOverall survival was measured. CHF: Cardiac Heart Failure. DM: Diabetes Mellitus. IHD: Ischemic Heart Disease. PVD: Peripheral Heart Disease. COPD: Chronic Obstructive Pulmonary Disease. Role of comorbidity varies by age70Pritchard 2006 \[[@CR68]\]639 premenopausal N+10Her2 amplificationHer2 corrected for age, N, ER, type of surgeryOverall survival was measured. Those with amplified Her2 have improved survival with CEF71Lee 2006 \[[@CR52]\](A) Adjuvant therapy − : 990. (B) Adjuvant treatment +: 1765Group A: 13\
Group B: 6.8.LVIGroup A: T, G, LVI, Htyp\
Group B: T, G, LVI, chemotherapy, hormonal therapyB: ER, age, HtypBreast cancer-specific survival was measured\
For patients without adjuvant treatment, role of G in survival was higher in the first 5 yrs. Role of Htyp was not significant for the first 5 yrs of FU^a^indicates the overlapping patients used by the same author to answer another research question; yrs: years; UV: Univariate analysis. MV: Multivariate analysis. MS: Menopausal Status; T: Tumour size; N: Nodal involvement; Htyp: Histological type; MI: Mitotic Index; G: Grade; PR: Progesterone Receptor status; ER: Oestrogen Receptor status; PCNA: proliferating cell nuclear antigen; mos: months; NR: Not Reported; AA: African American; age: is in year and indicate age at primary breast cancer unless otherwise state; NPI: Nottingham Prognostic Index; LVI: Lymphovascular Invasion; (Prognostic factor)\*(Prognostic factor): interaction between two factors; BMI: Body Mass Index; AMC: Average Microvessel Count; MAI: Mitotic Activity Index; AI: Apoptosis Index; FU: Follow-up; SES: Socioeconomic Status; BVI: Blood vessel Invasion; LMVD: Lymphatic Microvessel Density; LR: local recurrence; CVD: Cardiovascular Disease; DM: Diabetes Mellitus; RT: radiotherapy; ST: Systemic therapy; VEGFR: Vascular Endothelial Growth Factor Receptor; OS: Overall survival; BCS: Breast Cancer Specific Survival; NS: not significant; CHF: Cardiac Heart Failure; IHD: Ischemic Heart Disease. PVD: Peripheral Heart Disease. COPD: Chronic Obstructive Pulmonary. CEF: cyclophosphamide, epirubicin and fluorouracilTable 2Selected prognostic factors for long-term overall mortality of breast cancer (BC) patientsPatient groups basedHazard ratio (HR) for overall follow-up or survival probability (S) 10 years after diagnosisMorphology basedHazard ratio (HR) for overall follow-up or survival probability (S) 10 years after diagnosisMolecular basedHazard ratio (HR) for overall follow-up or survival probability (S) 10 years after diagnosisAge at diagnosis \[[@CR8]\]HR:Lymph node status \[[@CR31]\]HR:HER2\[[@CR69]\]HR:       \<35 vs. 35--441.4 (*P*: 0.07)  N≥1 vs. N02.4 (1.9--2.9)  \>500 vs. ≤5001.82 (1.1--2.9)      45--54 vs. 35--441.1 (ns)Metastases vs. N022.73 (16.1--32.2)Only in node-positive       55--64 vs. 35--442.0 (*P*: 0.000)      65--75 vs. 35--442.5 (*P*: 0.000)Period of diagnosis \[[@CR16]\]Relative survival^b^:Tumour size (mm)\[[@CR31]\]HR:Cell proliferation indexHR:      1972--197659%  T10--14 vs. T1--91.2 (0.8--1.9)(MAI)      1977--198664%  T15--19 vs. T1--91.7 (1.1--2.6)  \>10 vs. ≤10 \[[@CR10]\]1.02 (1.00--1.03)      1987--199170%  T20--29 vs. T1--92.5 (1.6--3.9)Only in node-positive patients  T30--49 vs. T1--93.8 (2.4--6.0)  T≥50 vs. T1--94.6 (2.9--7.6)Time after diagnosis \[[@CR16]\]Relative survival:Tumour grade \[[@CR44]\]HR:Gene expression profile \[[@CR74]\]S:    0 vs. 5 yrs after diagnosis  II vs. I2.5 (1.0--6.1)55% vs. 95%       Regional BC79% vs. 84%  III vs. I5.7(2.6--12.4)  Poor vs. good signature^f^       Locally advanced BC53% vs. 68%Socioeconomic status \[[@CR26]\]HR:Tumour type\[[@CR34]\]S:ER/PR status \[[@CR30]\]HR:       Intermediate vs. affluent1.2 (1.0--1.4)  Poor vs. excellent ^d,e^\<50% vs. \>80%  Positive vs. negative0.38 (0.02--1.06)       Deprived vs. affluent1.2 (0.99--1.53)LifestyleHR:       Body Mass Index              \<21 vs. 29+ kg/m^2^1.4 (0.97--2.00) \[[@CR85]\] ^c^       Physical activity              \< 3 vs. 23.9 MET-h/wk^*a*^0.56 (0.4--0.8) \[[@CR87]\]HR: Hazard ratio calculated within multivariate analysis of breast cancer patients followed for a median/mean of 10 years or longer ^a^ Metabolic equivalent task hours per week; ^b^ Estimates taken from graph; ^c^ Higher alcohol intake no significant effect on mortality. Significant trend of higher mortality for lowest compared to highest quintiles of fibre, lutein and zeaxanthin, calcium & protein intake; ^d^ Becomes larger as numbers of involved lymph nodes increases \[[@CR8]\]; ^e^ Excellent prognosis: tubular, invasive cribriform, mucinous, tubulolobular. Poor prognosis: mixed lobular, solid lobular, ductal and mixed ductal lobular; ^f^ unadjusted estimates

Healthier lifestyle generally increases long-term survival. Modifiable risk factors (such as alcohol consumption and obesity) not only affect incidence but also tumour' clinical behaviour and thus survival.

Although a lot is known about the prognosis for BC patients, effect of traditional prognostic factors appears to attenuate over time, leaving room for studies on the role of other and newer factors for long-term survival.
